A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2019
This article has no abstract
Epistemonikos ID: 3ee569e841b57ddc53b3984a89fb76613b4ae9e7
First added on: Apr 11, 2025